| Name | Title | Contact Details |
|---|
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers.
Founded in 2017, Action Behavior Centers (ABC) is a leading Applied Behavior Therapy (ABA) provider offering comprehensive services and support to improve the lives of children on the autism spectrum. The provider`s high-quality, center-based care combined with its dedication to helping young children reach their full potential has made ABC one of the fastest growing and highest quality providers in the industry. Headquartered in Austin, Texas, ABC operates 54 clinics in Texas, Arizona and Colorado.
Tanis Technical is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.